Nagoya Medical Center Trials

Nagoya Medical Center	Welcome, Profile Billing Logout

48 Trials

Active Trials Industry lead sponsorIndustry collaborator

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Nagai, Hirokazu

BRUIN CLL-321, NCT04666038: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

238

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

08/23

05/27

BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

250

Europe, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

07/25

08/26

BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting

500

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa

Loxo Oncology, Inc., Eli Lilly and Company

Lymphoma, Mantle-Cell

01/27

04/28

LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

	Jun 2025 - Jun 2025 : Updated safety run-in data for 2L+ r/r DLBCL/HGBL
	Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
	Sep 2021 - Dec 2021 : Submission for r/r DLBCL

Active, not recruiting

440

Europe, Canada, Japan, US, RoW

Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin

ADC Therapeutics S.A., ADC Therapeutics SA

Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

06/25

06/28

BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting

600

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

04/26

01/27

Coordinator, Research

CAMPLIFE, NCT06562296: Study Evaluating Several CAMPs in Nonhealing Diabetic Foot and Venous Leg Ulcers

Active, not recruiting

292

Amnion-Intermediate-Chorion, AIC, Amnion-Chorion-Amnion, ACA, Standard of Care, SOC

Cellution Biologics, SerenaGroup, Inc., LifeCell

Diabetic Foot Ulcer, Venous Leg Ulcer

12/26

07/27

NCT05078827: Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

Completed

458

Test Product (A): Fluorouracil Cream, 5% topical cream, Experimental, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., Active Comparator, Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India, Placebo Comparator

Encube Ethicals Pvt. Ltd., CBCC Global Research

Actinic Keratoses

11/22

12/22

ReMMi-D, NCT05853900: Study of Two Digital Therapeutics for the Prevention of Episodic Migraine

Completed

558

ReMMi-D Digital Therapeutic

Click Therapeutics, Inc.

Migraine, Episodic Migraine, Headache, Headache, Migraine

05/24

OPERA-T, NCT05238116 / 2021-004554-32: Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis ( Study)

Recruiting

123

Europe, Canada, US, RoW

PC945, Placebo

Pulmocide Ltd

Refractory IPA

03/26

04/26

NCT06004388: Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)

Completed

110

Click Digital Therapeutic

Click Therapeutics, Inc.

Migraine, Episodic Migraine, Headache, Headache, Migraine

05/24

06/24

SKOAP, NCT04504812: A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain

Completed

1937

Duloxetine, Cymbalta, Intra-Articular Injection, Nerve Procedure with long acting blocks, Nerve Procedure with nerve ablation, Pain Coping Skills Training, Best Practices

Johns Hopkins University, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Pacira Pharmaceuticals, Inc

Knee Osteoarthritis

04/25

CONVOKE, NCT05838625: Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia

Active, not recruiting

432

Digital Therapeutic

Click Therapeutics, Inc., Boehringer Ingelheim

Schizophrenia

06/25

07/25

NCT06067984: An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia

Active, not recruiting

Study App

Click Therapeutics, Inc., Boehringer Ingelheim

Schizophrenia, Negative Symptoms in Schizophrenia

06/25

NCT06365437: A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

Completed

Europe

TCD601, Siplizumab, Tacrolimus (TAC), Corticosteroids (CS), Mycophenolate Mofetil (MMF), ATG

ITB-Med LLC

Kidney Transplantation

12/24

PHYOX8, NCT05001269 / 2021-001083-16: Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function

Completed

Europe, Canada, Japan, US, RoW

nedosiran, DCR-PHXC

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Primary Hyperoxaluria, Primary Hyperoxaluria Type 1, Primary Hyperoxaluria Type 2, Primary Hyperoxaluria Type 3

02/25

CHASE, NCT05727878: Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED

Recruiting

US, RoW

KPI-012, KPI-012 Vehicle

Combangio, Inc, Kala Pharmaceuticals, Inc.

Persistent Corneal Epithelial Defect

09/25

06/26

NCT05733546: A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

Recruiting

102

Psilocybin, COMP360

COMPASS Pathways

Major Depressive Disorder

10/24

11/24

NCT04270175: Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Active, not recruiting

Daratumumab SC, Faspro, Pomalidomide, Dexamethasone

Weill Medical College of Cornell University, Janssen Scientific Affairs, LLC

Amyloid, AL Amyloidosis, Refractory AL Amyloidosis

09/25

09/27

NCT04803058: A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)

Active, not recruiting

US, RoW

TCD601

ITB-Med LLC

Kidney Transplantation

03/27

03/30

STRIDE, NCT06025110: A Study of TCD601 (siplizumab) in New Onset Type 1 Diabetes Patients

Active, not recruiting

Europe

TCD601, Placebo

ITB-Med LLC

Diabetes Mellitus, Type 1

01/27

ASCEND, NCT05669001: A Study of TCD601 in de Novo Renal Transplant Recipients

Active, not recruiting

TCD601, siplizumab, belatacept, ATG, antithymocyte globulin, TAC, tacrolimus, MPA, mycophenolic acid, Corticosteroids

ITB-Med LLC

Renal Transplantation

07/25

10/26

NCT04311632: A Dose Escalation Study in de Novo Renal Transplantation

Completed

TCD601, Tacrolimus (TAC), Corticosteroids (CS), Mycophenolate Mofetil (MMF), ATG

ITB-Med LLC

Kidney Transplantation

10/23

NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Active, not recruiting

2190

SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD

NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC

Opioid Use Disorder (OUD)

12/26

NCT04803006: A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)

Active, not recruiting

TCD601

ITB-Med LLC

Kidney Transplantation

07/27

07/30

AURORA, NCT06453668: A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients

Active, not recruiting

Europe

TCD601, siplizumab

ITB-Med LLC

ALS

11/26

PBL-0405-01, NCT06273852: A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

Recruiting

PBA-0405, PB004.22.0405.aF

Pure Biologics S.A., Presage Biosciences

Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer

03/25

MST01-AZN-05, NCT06366451: PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Recruiting

Rilvegostomig, AZD2936, Volrustomig, MEDI5752, Sabestomig, AZD7789, AZD9592, Pembrolizumab, Keytruda, MK-3475, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab

Presage Biosciences, AstraZeneca

Head and Neck Squamous Cell Carcinoma

02/25

04/25

OP-1250-003, NCT05508906: Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus

Recruiting

155

US, RoW

OP-1250, Ribociclib, KISQALI®, Alpelisib, PIQRAY®, Everolimus

Olema Pharmaceuticals, Inc., Novartis

Metastatic Breast Cancer, Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer

05/26

06/26

RAINIER, NCT06634394: APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

Recruiting

APVO436, Venetoclax, venclexta, Azacitidine, vidaza

Aptevo Therapeutics

Acute Myeloid Leukemia (AML)

10/27

03/28

NCT06798454: Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)

Recruiting

RoW

PVT201, Navacim, Placebo, normal saline, 0.9% NaCl

Parvus Therapeutics, Inc., Avance Clinical Pty Ltd.

Primary Biliary Cholangitis (PBC)

06/25

NCT04541108: Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Recruiting

Rilvegostomig, AZD2936, Volrustomig, MEDI5752, Sabestomig, AZD7789, Pembrolizumab, Keytruda, MK-3475

Presage Biosciences, Merck Sharp & Dohme LLC

Solid Tumor

12/31

NCT06802328: Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients

Available

N/A

Foralumab TZLS-401 50 µg

Tiziana Life Sciences LTD

Non-Active Secondary Progressive Multiple Sclerosis

NCT06136936: A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia

Completed

N/A

CT-156-C-001

Click Therapeutics, Inc., Boehringer Ingelheim

Schizophrenia

01/24

02/24

NCT05222581: Engineering Evaluation of a Breast Pump Device

Completed

N/A

Prototypes of breast shield and Freedom Double Electric Breast Pump

Momtech Inc.

Healthy, Breast Pumping

06/24

09/24

NCT06136923: An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer

Completed

N/A

194

CT-100-D-004-A, CT-100-D-004-B

Click Therapeutics, Inc.

Multiple Sclerosis, Lung Cancer, Breast Cancer

04/24

05/24

LOCAL, NCT04968847: FemaSeed Artificial Insemination Trial

Completed

N/A

314

FemaSeed Localized Directional Insemination

Femasys Inc.

Infertility, Male Factor

12/23

04/24

CT-100-D-003, NCT06275659: An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis

Completed

N/A

120

CT-100-004-A, CT-100-004-B

Click Therapeutics, Inc.

Psoriasis, Atopic Dermatitis

02/24

NCT05119842: APrevent-VOIS-Implant-002 - a Two-Part, Open-Label, Non-Randomized Multicenter Study

Recruiting

N/A

Europe, US

APrevent® VOIS-Implant

APrevent Biotech GmbH

Paralysis, Unilateral, Vocal Cord

09/25

09/26

CoMind EFS, NCT06368648: CoMind Early Feasibility Study

Recruiting

N/A

581

CoMind Technologies Limited, Lindus Health

Intracranial Pressure, Intracranial Pressure Changes, Traumatic Brain Injury, Intracerebral Hemorrhage, Encephalitis, Encephalopathy, Hydrocephalus, Stroke, Autoregulation

10/25

NCT05006404: Autus Valve Pivotal Study

Recruiting

N/A

Pulmonary Valve Replacement Surgery

Autus Valve Technologies, Inc.

Congenital Heart Disease

08/26

02/36

MASTR, NCT05243966: Myriad™ Augmented Soft Tissue Reconstruction Registry

Recruiting

N/A

800

Myriad Matrix™ and Myriad Morcells™

Aroa Biosurgery Limited

Abdominal Wound Dehiscence, Necrotizing Soft Tissue Infection, Lower Extremity Wound, Pilonidal Sinus, Anal Fistula, Hidradenitis Suppurativa, Pressure Injury

01/28

01/29

NCT06770998: A Study of a Novel EEG Neurofeedback System for PTSD Treatment

Not yet recruiting

N/A

250

EEG-neurofeedback training, Prism training, amyg-EFP training, active Prism training, Sham training, sham Prism training

Foundation for Atlanta Veterans Education and Research, Inc., GrayMatters Health Ltd., Rochester Institute of Technology, New York University Grossman School of Medicine, Atlanta VA Medical Center, Birmingham VA Health Care System, Ralph H. Johnson VA Medical Center, VA Boston Healthcare System, CTP Inc, BioStats Statistical Consulting Ltd, ShareCRF, United States Department of Defense

Stress Disorders, Post-Traumatic

06/27

08/27

FASTR-TEN, NCT06867185: Evaluating Therapeutic Electrical Stimulation to Improve Nerve Healing After Surgical Repair of Digital Nerve Injuries

Recruiting

N/A

Brief Electrical Stimulation Therapy, BES, Therapeutic Electrical Stimulation, Electrical Stimulation, Digital Nerve Repair, Nerve Repair

Checkpoint Surgical Inc.

Digital Nerve Injury, Nerve Injury, Nerve Reconstruction, Nerve Trauma, Digital Nerve Lesion

12/26

03/27

PHONES, NCT04662320: Promoting Healing of Nerves Through Electrical Stimulation

Active, not recruiting

N/A

100

Checkpoint BEST System, Brief Electrical Stimulation (BES) Therapy

Checkpoint Surgical Inc., Congressionally Directed Medical Research Programs

Cubital Tunnel Syndrome, Nerve Compression, Nerve Injury, Ulnar Neuropathies

12/25

FINALE, NCT05977751: Prospective Multi-Center Trial for FemBloc Permanent Birth Control

Recruiting

N/A

573

FemBloc

Femasys Inc.

Contraception

12/29

06/31

PHINEST, NCT05884125: Promoting Healing of Injured Nerves With Electrical Stimulation Therapy

Recruiting

N/A

Checkpoint BEST System, Brief Electrical Stimulation (BES) Therapy

Checkpoint Surgical Inc., Congressionally Directed Medical Research Programs

Nerve Injury, Peripheral Nerve Injuries, Peripheral Nerve Injury Upper Limb, Nerve Palsy

06/27

NCT05678530: Observational, Non-Interventional Study Supporting Validation of VO2Max Estimation Methods Using Results in Patients Receiving Standard of Care Cardiopulmonary Exercise Tests (CPET)

Recruiting

N/A

400

Canada, US

Prolaio

Cardiopulmonary

01/26

Watanabe, Satoshi

NCT06332885: Zephyr Valve Japan Post-Marketing Surveillance

Recruiting

N/A

140

Japan

Zephyr Endobronchial Valve

Pulmonx Corporation

Emphysema, COPD, Severe Emphysema

03/27

03/28

Katayama, Masao

No trials found

Futamura, Masaki

No trials found

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Nagai, Hirokazu

Active, not recruiting

238

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

08/23

05/27

BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

250

Europe, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

07/25

08/26

BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting

500

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa

Loxo Oncology, Inc., Eli Lilly and Company

Lymphoma, Mantle-Cell

01/27

04/28

LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

	Jun 2025 - Jun 2025 : Updated safety run-in data for 2L+ r/r DLBCL/HGBL
	Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
	Sep 2021 - Dec 2021 : Submission for r/r DLBCL

Active, not recruiting

440

Europe, Canada, Japan, US, RoW

Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin

ADC Therapeutics S.A., ADC Therapeutics SA

Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

06/25

06/28

Active, not recruiting

600

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

04/26

01/27

Coordinator, Research

CAMPLIFE, NCT06562296: Study Evaluating Several CAMPs in Nonhealing Diabetic Foot and Venous Leg Ulcers

Active, not recruiting

292

Amnion-Intermediate-Chorion, AIC, Amnion-Chorion-Amnion, ACA, Standard of Care, SOC

Cellution Biologics, SerenaGroup, Inc., LifeCell

Diabetic Foot Ulcer, Venous Leg Ulcer

12/26

07/27

NCT05078827: Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

Completed

458

Encube Ethicals Pvt. Ltd., CBCC Global Research

Actinic Keratoses

11/22

12/22

ReMMi-D, NCT05853900: Study of Two Digital Therapeutics for the Prevention of Episodic Migraine

Completed

558

ReMMi-D Digital Therapeutic

Click Therapeutics, Inc.

Migraine, Episodic Migraine, Headache, Headache, Migraine

05/24

Recruiting

123

Europe, Canada, US, RoW

PC945, Placebo

Pulmocide Ltd

Refractory IPA

03/26

04/26

NCT06004388: Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)

Completed

110

Click Digital Therapeutic

Click Therapeutics, Inc.

Migraine, Episodic Migraine, Headache, Headache, Migraine

05/24

06/24

SKOAP, NCT04504812: A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain

Completed

1937

Duloxetine, Cymbalta, Intra-Articular Injection, Nerve Procedure with long acting blocks, Nerve Procedure with nerve ablation, Pain Coping Skills Training, Best Practices

Johns Hopkins University, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Pacira Pharmaceuticals, Inc

Knee Osteoarthritis

04/25

CONVOKE, NCT05838625: Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia

Active, not recruiting

432

Digital Therapeutic

Click Therapeutics, Inc., Boehringer Ingelheim

Schizophrenia

06/25

07/25

NCT06067984: An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia

Active, not recruiting

Study App

Click Therapeutics, Inc., Boehringer Ingelheim

Schizophrenia, Negative Symptoms in Schizophrenia

06/25

NCT06365437: A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

Completed

Europe

TCD601, Siplizumab, Tacrolimus (TAC), Corticosteroids (CS), Mycophenolate Mofetil (MMF), ATG

ITB-Med LLC

Kidney Transplantation

12/24

PHYOX8, NCT05001269 / 2021-001083-16: Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function

Completed

Europe, Canada, Japan, US, RoW

nedosiran, DCR-PHXC

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Primary Hyperoxaluria, Primary Hyperoxaluria Type 1, Primary Hyperoxaluria Type 2, Primary Hyperoxaluria Type 3

02/25

CHASE, NCT05727878: Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED

Recruiting

US, RoW

KPI-012, KPI-012 Vehicle

Combangio, Inc, Kala Pharmaceuticals, Inc.

Persistent Corneal Epithelial Defect

09/25

06/26

Recruiting

102

Psilocybin, COMP360

COMPASS Pathways

Major Depressive Disorder

10/24

11/24

NCT04270175: Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Active, not recruiting

Daratumumab SC, Faspro, Pomalidomide, Dexamethasone

Weill Medical College of Cornell University, Janssen Scientific Affairs, LLC

Amyloid, AL Amyloidosis, Refractory AL Amyloidosis

09/25

09/27

NCT04803058: A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)

Active, not recruiting

US, RoW

TCD601

ITB-Med LLC

Kidney Transplantation

03/27

03/30

STRIDE, NCT06025110: A Study of TCD601 (siplizumab) in New Onset Type 1 Diabetes Patients

Active, not recruiting

Europe

TCD601, Placebo

ITB-Med LLC

Diabetes Mellitus, Type 1

01/27

ASCEND, NCT05669001: A Study of TCD601 in de Novo Renal Transplant Recipients

Active, not recruiting

TCD601, siplizumab, belatacept, ATG, antithymocyte globulin, TAC, tacrolimus, MPA, mycophenolic acid, Corticosteroids

ITB-Med LLC

Renal Transplantation

07/25

10/26

NCT04311632: A Dose Escalation Study in de Novo Renal Transplantation

Completed

TCD601, Tacrolimus (TAC), Corticosteroids (CS), Mycophenolate Mofetil (MMF), ATG

ITB-Med LLC

Kidney Transplantation

10/23

NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Active, not recruiting

2190

SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD

NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC

Opioid Use Disorder (OUD)

12/26

NCT04803006: A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)

Active, not recruiting

TCD601

ITB-Med LLC

Kidney Transplantation

07/27

07/30

AURORA, NCT06453668: A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients

Active, not recruiting

Europe

TCD601, siplizumab

ITB-Med LLC

ALS

11/26

PBL-0405-01, NCT06273852: A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

Recruiting

PBA-0405, PB004.22.0405.aF

Pure Biologics S.A., Presage Biosciences

Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer

03/25

MST01-AZN-05, NCT06366451: PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Recruiting

Presage Biosciences, AstraZeneca

Head and Neck Squamous Cell Carcinoma

02/25

04/25

OP-1250-003, NCT05508906: Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus

Recruiting

155

US, RoW

OP-1250, Ribociclib, KISQALI®, Alpelisib, PIQRAY®, Everolimus

Olema Pharmaceuticals, Inc., Novartis

Metastatic Breast Cancer, Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer

05/26

06/26

RAINIER, NCT06634394: APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

Recruiting

APVO436, Venetoclax, venclexta, Azacitidine, vidaza

Aptevo Therapeutics

Acute Myeloid Leukemia (AML)

10/27

03/28

NCT06798454: Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)

Recruiting

RoW

PVT201, Navacim, Placebo, normal saline, 0.9% NaCl

Parvus Therapeutics, Inc., Avance Clinical Pty Ltd.

Primary Biliary Cholangitis (PBC)

06/25

NCT04541108: Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Recruiting

Rilvegostomig, AZD2936, Volrustomig, MEDI5752, Sabestomig, AZD7789, Pembrolizumab, Keytruda, MK-3475

Presage Biosciences, Merck Sharp & Dohme LLC

Solid Tumor

12/31

NCT06802328: Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients

Available

N/A

Foralumab TZLS-401 50 µg

Tiziana Life Sciences LTD

Non-Active Secondary Progressive Multiple Sclerosis

NCT06136936: A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia

Completed

N/A

CT-156-C-001

Click Therapeutics, Inc., Boehringer Ingelheim

Schizophrenia

01/24

02/24

NCT05222581: Engineering Evaluation of a Breast Pump Device

Completed

N/A

Prototypes of breast shield and Freedom Double Electric Breast Pump

Momtech Inc.

Healthy, Breast Pumping

06/24

09/24

NCT06136923: An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer

Completed

N/A

194

CT-100-D-004-A, CT-100-D-004-B

Click Therapeutics, Inc.

Multiple Sclerosis, Lung Cancer, Breast Cancer

04/24

05/24

LOCAL, NCT04968847: FemaSeed Artificial Insemination Trial

Completed

N/A

314

FemaSeed Localized Directional Insemination

Femasys Inc.

Infertility, Male Factor

12/23

04/24

CT-100-D-003, NCT06275659: An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis

Completed

N/A

120

CT-100-004-A, CT-100-004-B

Click Therapeutics, Inc.

Psoriasis, Atopic Dermatitis

02/24

NCT05119842: APrevent-VOIS-Implant-002 - a Two-Part, Open-Label, Non-Randomized Multicenter Study

Recruiting

N/A

Europe, US

APrevent® VOIS-Implant

APrevent Biotech GmbH

Paralysis, Unilateral, Vocal Cord

09/25

09/26

CoMind EFS, NCT06368648: CoMind Early Feasibility Study

Recruiting

N/A

581

CoMind Technologies Limited, Lindus Health

Intracranial Pressure, Intracranial Pressure Changes, Traumatic Brain Injury, Intracerebral Hemorrhage, Encephalitis, Encephalopathy, Hydrocephalus, Stroke, Autoregulation

10/25

NCT05006404: Autus Valve Pivotal Study

Recruiting

N/A

Pulmonary Valve Replacement Surgery

Autus Valve Technologies, Inc.

Congenital Heart Disease

08/26

02/36

MASTR, NCT05243966: Myriad™ Augmented Soft Tissue Reconstruction Registry

Recruiting

N/A

800

Myriad Matrix™ and Myriad Morcells™

Aroa Biosurgery Limited

Abdominal Wound Dehiscence, Necrotizing Soft Tissue Infection, Lower Extremity Wound, Pilonidal Sinus, Anal Fistula, Hidradenitis Suppurativa, Pressure Injury

01/28

01/29

NCT06770998: A Study of a Novel EEG Neurofeedback System for PTSD Treatment

Not yet recruiting

N/A

250

EEG-neurofeedback training, Prism training, amyg-EFP training, active Prism training, Sham training, sham Prism training

Stress Disorders, Post-Traumatic

06/27

08/27

FASTR-TEN, NCT06867185: Evaluating Therapeutic Electrical Stimulation to Improve Nerve Healing After Surgical Repair of Digital Nerve Injuries

Recruiting

N/A

Brief Electrical Stimulation Therapy, BES, Therapeutic Electrical Stimulation, Electrical Stimulation, Digital Nerve Repair, Nerve Repair

Checkpoint Surgical Inc.

Digital Nerve Injury, Nerve Injury, Nerve Reconstruction, Nerve Trauma, Digital Nerve Lesion

12/26

03/27

PHONES, NCT04662320: Promoting Healing of Nerves Through Electrical Stimulation

Active, not recruiting

N/A

100

Checkpoint BEST System, Brief Electrical Stimulation (BES) Therapy

Checkpoint Surgical Inc., Congressionally Directed Medical Research Programs

Cubital Tunnel Syndrome, Nerve Compression, Nerve Injury, Ulnar Neuropathies

12/25

FINALE, NCT05977751: Prospective Multi-Center Trial for FemBloc Permanent Birth Control

Recruiting

N/A

573

FemBloc

Femasys Inc.

Contraception

12/29

06/31

PHINEST, NCT05884125: Promoting Healing of Injured Nerves With Electrical Stimulation Therapy

Recruiting

N/A

Checkpoint BEST System, Brief Electrical Stimulation (BES) Therapy

Checkpoint Surgical Inc., Congressionally Directed Medical Research Programs

Nerve Injury, Peripheral Nerve Injuries, Peripheral Nerve Injury Upper Limb, Nerve Palsy

06/27

NCT05678530: Observational, Non-Interventional Study Supporting Validation of VO2Max Estimation Methods Using Results in Patients Receiving Standard of Care Cardiopulmonary Exercise Tests (CPET)

Recruiting

N/A

400

Canada, US

Prolaio

Cardiopulmonary

01/26

Watanabe, Satoshi

NCT06332885: Zephyr Valve Japan Post-Marketing Surveillance

Recruiting

N/A

140

Japan

Zephyr Endobronchial Valve

Pulmonx Corporation

Emphysema, COPD, Severe Emphysema

03/27

03/28

Katayama, Masao

No trials found

Futamura, Masaki

No trials found

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites